

4/27/99

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR Part 807.92.

The assigned 510(k) number is: K 990870

1. Date of summary: February 18, 1999
2. Submitted by: Redwood Biotech 3573 Westwind Blvd. Santa Rosa, CA 95403
TEL 707-577-7959
FAX 707-577-0365
Contact: Robert Mount
3. Device Name: Redi-Test THC
4. Device Classification: Class II, 862.3650, Panel 91 Toxicology
5. Device description: The Redi-Test THC is an immunochromatographic based one step *in vitro* test.
6. Intended Use: The Redi-Test is designed for the qualitative determination of cannabinoids (THC) and its metabolites in human urine specimens. The presence of 11-nor- Δ^9 -THC-9-COOH in human urine as low as 50 ng/ml can be detected. This test is for use in clinical laboratories by health care professionals and forensic professionals only.
7. Substantial Equivalence: The Redi-Test was found substantially equivalent to the DRI, Cannabinoids Enzyme Immunoassay. Both products are immunoassays and use specific antibodies to detect the major metabolite of cannabinoids. Both assays are preliminary screens for human urine and require confirmation with alternate methods such as GC/MS. The sensitivity of the tests are similar, the DRI test detects 11-Hydroxy- Δ^9 -THC at a cut off of 20ng/mL and the Redi-Test detects this metabolite at a cut off of 50ng/mL. GC/MS confirmed that both tests identified samples below 24.7ng/mL negative and above 31ng/mL positive.
The tests demonstrated 99% correlation when 100 specimens (50 positive and 50 negative) were compared. The tests are similar in sensitivity, specificity, accuracy and precision.

Conclusion:

The Cannabinoid Enzyme Immunoassay and the Redi-Test THC are substantially equivalent in performance characteristics. The correlation of the two tests was 99%.



APR 27 1999

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Redwood Biotech Inc.
C/O Ms. Janis Freestone
Advantage Diagnostics Corporation
520 Weddell Drive, Suite B
Sunnyvale, California 94089

Re: K990870
Trade Name: Redi-Test THC
Regulatory Class: II
Product Code: LDJ
Dated: March 10, 1999
Received: March 16, 1999

Dear Ms. Freestone:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive style with a large initial 'S'.

Steven I. Gutman, M.D, M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510k Number: K990870

Device Name:
Redi-Test THC

Indications for Use:

The Redi-Test THC is a rapid immunochromatographic competitive assay used to screen human urine for the presence of cannabinoids at a cutoff concentration of 50ng/mL. The test is qualitative and provides only a preliminary analytical result which must be confirmed by an alternate methodology preferably GC/MS.

Dean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K990870

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)

○